**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 77211

**Manuscript Type:** CASE REPORT

**Imaging findings of immunoglobin G4-related hypophysitis: A case report**

Lv K *et al*. A case of IgG4-related hypophysitis

Kun Lv, Xin Cao, Dao-Ying Geng, Jun Zhang

**Kun Lv, Xin Cao, Dao-Ying Geng, Jun Zhang,** Department of Radiology, Huashan Hospital, Fudan University, Shanghai 200040, China

**Kun Lv, Xin Cao, Dao-Ying Geng, Jun Zhang,** Institute of Functional and Molecular Medical Imaging, Fudan University, Shanghai 200040, China

**Kun Lv, Xin Cao, Dao-Ying Geng, Jun Zhang,** Center for Shanghai Intelligent Imaging for Critical Brain Diseases Engineering and Technology Research, Science and Technology Commission of Shanghai Municipality, Shanghai 200003, China

**Kun Lv, Xin Cao, Dao-Ying Geng, Jun Zhang,** Institute of Intelligent Imaging Phenomics, International Human Phenome Institutes (Shanghai), Shanghai 200433, China

**Author contributions:** Geng DY designed the outline of the case report; Lv K wrote the first draft of the manuscript; Cao X edited the manuscript for important intellectual content; Zhang J and Lv K revised and edited the final version of the manuscript; all authors contributed to this article and approved the submitted version.

**Supported by** National Key R&D Program of China, No. 2019YFC0120602; Clinical Research Plan of SHDC, No. SHDC2020CR3020A; Research Startup Fund of Huashan Hospital, Fudan University, No. 2021QD035; Shanghai Municipal Commission of Science and Technology, No. 22S31905300; and Greater Bay Area Institute of Precision Medicine (Guangzhou), No. KCH2310094.

**Corresponding author: Dao-Ying Geng, MD, PhD, Chief Doctor,** Department of Radiology, Huashan Hospital, Fudan University, No. 12 Wulumuqi Middle Road, Shanghai 200040, China. gdy\_2019@163.com

**Received:** April 20, 2022

**Revised:** July 4, 2022

**Accepted: August 16, 2022**

**Published online:**

**Abstract**

BACKGROUND

Immunoglobin G4 (IgG4)-related hypophysitis (IgG4-RH) is a rare form of IgG4-related disease (IgG4-RD), which often manifests as a single organ disease and is easily misdiagnosed as a pituitary tumor clinically and by imaging. There are few reports of imaging findings of IgG4-RH. Therefore, we describe a case of IgG4-RH, which mimicked a pituitary macroadenoma, that was detected by computed tomography (CT) and magnetic resonance imaging (MRI), and review the previous literature in order to further the understanding of IgG4-RH.

CASE SUMMARY

A 47-year-old man presented with a history of blurred vision for more than 2 mo, without other symptoms. A preoperative unenhanced CT scan revealed a slightly hyperdense mass in the sellar region measuring 2.5 cm × 2.3 cm × 1.8 cm, with a CT value of 45 HU. T1-weighted imaging (T1WI) and T2-weighted imaging showed iso-hypointensity, and gadolinium contrast-enhanced T1WI showed obvious homogeneous enhancement. The MRI revealed involvement of the pituitary gland and stalk. Preoperative laboratory tests revealed abnormal pituitary hormone levels, including an increased prolactin level, and decreased levels of insulin-like growth factor, dehydroepiandrosterone, and testosterone. The lesion was surgically resected. Postoperative histopathological examination of a tissue sample and an elevated serum IgG4 level confirmed the diagnosis of IgG4-RH. The patient was treated with cortisone acetate postoperatively and made a good recovery without developing any neurological deficit.

CONCLUSION

An elevated serum IgG4 concentration is the main clue for diagnosis of IgG4-RD. Imaging combined with laboratory testing is useful for preoperative diagnosis of IgG4-RH.

**Key Words:** Immunoglobin G4-related disease; Pituitary; Macroadenoma; Inflammation; Hypophysitis; Case report

Lv K, Cao X, Geng DY, Zhang J. Imaging findings of immunoglobin G4-related hypophysitis: A case report. *World J Clin Cases* 2022; In press

**Core Tip:** Immunoglobin G4 (IgG4)-related hypophysitis (IgG4-RH) is a rare form of IgG4-related disease, which is easily misdiagnosed as a pituitary tumor. IgG4-RH commonly occurs in middle-aged and older men and is characterized by hypointensity on T2-weighted imaging and homogeneous and obvious enhancement on gadolinium contrast-enhanced T1-weighted imaging, accompanied by hypopituitarism. The imaging findings help to differentiate it from pituitary tumors. An elevated serum IgG4 level is the main clue to the diagnosis of IgG4-RH, and imaging, histopathology, or response to glucocorticoid therapy can be used to confirm the diagnosis.

**INTRODUCTION**

The most common immunoglobin G4 (IgG4)-related disease (IgG4-RD) is type I autoimmune pancreatitis, followed by head and neck lesions that usually involve the salivary gland, orbit, or thyroid. IgG4-RD of the central nervous system (CNS) is rare. IgG4-RD usually involves multiple systems, but can affect the CNS alone[1,2]. When IgG4-RD involves the CNS, it usually involves the pituitary gland and pituitary stalk, collectively referred to as IgG4-related hypophysitis (IgG4-RH)[3]. Although hypertrophic dura mater meningitis and hypophysitis are recognized as relatively common manifestations of involved CNS, there are few reports of imaging findings of IgG4-RH, making the noninvasive, definitive diagnosis more difficult. Although cases of intracranial IgG4-RD have been reported[4,5], reports of IgG4-RH are relatively rare, though there have been a few reports of head and neck IgG4-RD. IgG4-RH occurs predominantly in adults aged over 60 years (average age: 62 years), with a male preponderance (male:female ratio approximately 3.6:1)[6], and is easily misdiagnosed as a pituitary tumor, lymphoid tissue hyperplasia, or other types of hypophysitis (such as lymphocytic, granulomatous, and immune checkpoint inhibitor-related hypophysitis)[7]. It is important to differentiate IgG4-RH from these conditions because their treatment and prognosis are different. Imaging examination is an important method for noninvasive diagnosis, and magnetic resonance imaging (MRI) is the gold standard method for the diagnosis of pituitary diseases. Therefore, it is necessary to supplement knowledge of the imaging characteristics of IgG4-RH. We herein describe a case of IgG4-RH mimicking a pituitary macroadenoma that was detected by computed tomography (CT) and MRI, and review the previous literature.

**CASE PRESENTATION**

***Chief complaints***

In July 2021, a 47-year-old man presented with a history of blurred vision for more than 2 mo.

***History of present illness***

The patient had developed blurred vision more than 2 mo previously without any obvious precipitating factor, and had subsequently experienced progressive worsening of the symptoms. He did not report any dizziness, headache, nausea, vomiting, limb weakness, loss of consciousness, facial changes, or sexual dysfunction. His mood was normal and he reported a healthy appetite, normal sleeping pattern, normal bowel movements, and no weight loss.

***History of past illness***

The patient did not have any past illnesses of note.

***Personal and family history***

The patient had no special personal and family history.

***Physical examination***

Physical examination revealed decreased visual acuity, without any other abnormal neurological signs.

***Laboratory examinations***

Preoperative laboratory examination showed an increased prolactin level (49.96 ng/mL; normal range: 3.86–22.80 ng/mL); decreased levels of insulin-like growth factor: 25.3 μg/L; normal range: 94.0–284.0 μg/L), dehydroepiandrosterone (DHEA: 0.1 μmol/L; normal range: 1.91–13.40 μmol/L), and testosterone (0.09 μmol/L; normal range: 9.90–27.8 μmol/L); and levels of thyroid-stimulating hormone (TSH), growth hormone, and adrenocorticotropic hormone within the normal range. Postoperative laboratory tests revealed a decrease in the prolactin level (20.86 ng/mL) to within the normal range, and decreased levels of TSH (0.16 mLU/L; normal range: 0.550–4.780 mLU/L), DHEA (0.03 μmol/L), and testosterone (0.09 μmol/L). A serological IgG4 examination was subsequently performed. The serum IgG4 level was elevated (2.98 g/L; normal range: 0.03–2.01 g/L).

***Imaging examinations***

An unenhanced CT scan revealed a slightly hyperdense mass in the sellar region measuring 2.5 cm × 2.3 cm × 1.8 cm with a CT value of 45 HU (Figure 1). This was followed by an MRI scan (Figure 2). T1-weighted imaging (T1WI) and T2-weighted imaging (T2WI) revealed iso-hypointensity with an hourglass-shaped mass (“hourglass sign”), and gadolinium contrast-enhanced T1WI showed obvious homogeneous enhancement, without hyperintensity of the posterior lobe of the pituitary gland. The MRI findings indicated involvement of the pituitary gland and stalk. The mass was protruding upward and compressing the optic chiasm.

**FINAL DIAGNOSIS**

Based on the above findings, the patient was diagnosed with IgG4-RH.

**TREATMENT**

The pituitary lesion was resected, and the patient was treated with cortisone acetate postoperatively.

**OUTCOME AND FOLLOW-UP**

Postoperative histopathological examination (Figure 3) of the lesion showed abundant plasma cells and lymphocyte infiltration with local fibrosis. Immunohistochemistry revealed IgG4 (+)/IgG (+) > 40%, and IgG4 (+) cells > 10/high-powered field (HPF). The patient’s postoperative recovery was good, and he did not develop any neurological deficit. He had not experienced a recurrence at the time of his most recent follow-up in March 2022.

**DISCUSSION**

IgG4-RD is a benign, immune-mediated disease, involving multiple organs, which has features in common with several malignancies, infections, and inflammatory diseases. The histopathological findings are consistent in a wide range of organ systems[7]. The three main pathological features of IgG4-RD are lymphoplasmacytic infiltration, storiform fibrosis, and obliterative phlebitis. Eosinophil infiltration is common, but neutrophil infiltration is rare[8]. Storiform fibrosis, in which collagen fibers are arranged radially, is a typical feature of IgG4-RD, but may not be detected in biopsy tissue due to patchy distribution. In addition, there is some organ-specific variability in its manifestations, such as a lack of storiform fibrosis in the lacrimal glands and lymph nodes, and a low incidence of obliterative phlebitis in the salivary glands[8,9]. IgG4-RD usually has a subacute presentation, with symptoms and organ dysfunction existing for months or even years before diagnosis. In specific organs, the disease may progress slowly, occasionally resolves spontaneously, and may temporarily improve or remain dormant for long periods[7]. The clinical manifestations may differ according to the site. IgG4-RH is characterized by dysfunction of the anterior and posterior pituitary lobes and hormonal disturbances. When the anterior pituitary is involved, it often manifests as hyposexuality, hypogonadism, hypothyroidism, and adrenal hypofunction. When the posterior pituitary or pituitary stalk is involved, it often manifests as polyuria and polydipsia. According to previous reports, hypopituitarism and diabetes insipidus are present in 83% and 72% of cases, respectively, and both syndromes are present in 59% of cases with pituitary involvement[10,11]. It has also been reported that the disease may manifest as normal pituitary function in the early stages of onset[12]. Large lesions involving adjacent structures can cause corresponding symptoms, such as visual impairment when the optic nerve/chiasm is involved. Although biopsy is the gold standard for diagnosis in most cases, clinicopathological correlation needs to be confirmed, even if there is supporting histopathological evidence. An increased serum IgG4 level is the main clue to the diagnosis of IgG4-RH[13]. The two main diagnostic criteria for IgG4-RD are: (1) Serum IgG4 concentration > 135 mg/dL; and (2) > 40% of IgG+ plasma cells being IgG4+ and > 10 IgG4+ cells/HPF of biopsy sample in any affected organ[14]. However, the serum IgG4 level alone lacks sensitivity and specificity[7]. The serum IgG4 level is diagnostic if it is more than four times the upper limit of normal. Moreover, a normal serum IgG4 level does not exclude a diagnosis of IgG4-RD. Although imaging findings also lack specificity, imaging modalities such as CT, MRI, and positron emission tomography play an important role in the noninvasive diagnosis of IgG4-RH.

IgG4-RH is usually confined to the pituitary, rather than occurring in multiple organs as in other forms of IgG4-RD[6]. This case only reported pituitary lesions, and showed panhypophysitis. However, the presence of lesions in other body parts cannot be excluded because of a lack systemic examination. The inflammatory process of IgG4-RH can be divided into anterior lobe lesions, posterior lobe and pituitary stalk lesions, and panhypophysitis. Panhypophysitis is the most common form[10]. To our knowledge, there are few reports on the imaging findings of IgG4-RH, although there have been a few reports of the imaging findings of IgG4-RD in the head and neck[15,16]. Based on previous reports[17,18] and the imaging findings in this case, the imaging findings of IgG4-RH are enlargement of pituitary and/or pituitary stalk with a clear boundary and regular morphology. Necrosis and calcification are rare and the diagnosis should be questioned if they are present[7,16]. A cystic structure can be seen in the enlarged gland, and empty sellar syndrome can occur after glucocorticoid treatment[10]. In addition, CT shows homogeneous hypodensity to mild hyperdensity, usually without bone destruction, but compressive bone erosion or osteosclerosis may be present. Compared with the gray matter, the lesion is usually isohypointense on both T1WI and T2WI, which corresponds with an increased number of cells and degree of fibrosis in the lesion on histopathology. Hyperintensity of the posterior pituitary lobe on T1WI is usually absent, and gadolinium contrast-enhanced T1WI shows homogeneous, obvious, and gradual enhancement, which may be associated with the inflammatory process[15]. Because of the similarity in imaging findings, it is usually necessary to differentiate IgG4-RH from pituitary macroadenoma, histiocytosis, and other relatively common types of hypophysitis, such as lymphocytic, granulomatous, and immune checkpoint inhibitor-related hypophysitis. Unlike IgG4-RH, which is more common in middle-aged and older men, these diseases are more common in young and middle-aged women[6]. IgG4-RH should be distinguished from pituitary macroadenomas that require surgical intervention. Pituitary adenomas over 10 mm are called macroadenomas. The mass effect usually causes bone erosion and sellar enlargement. In an epidemiological study, 74% of macroadenomas were non-functional[19]. The intensity of a pituitary adenoma on T1WI is similar to that of the gray matter, but lower than that of the pituitary gland. Hyperintensity can be seen on T1WI if hemorrhage is present. The intensity on T2WI is variable due to hemorrhage, cyst, or necrosis. Pituitary macroadenoma usually invades the surrounding area, and the degree of enhancement after enhanced scan is usually lower than that of hypophysitis[20]. The underlying diagnosis of histiocytosis is often known, or is suggested by the presence of associated bone lesions and other intracranial mass lesions[21]. Immune checkpoint inhibitor–induced hypophysitis is characterized by geographic hypoenhancing lesions in the anterior lobe of the pituitary gland on CE-T1WI[22]. Lymphocytic hypophysitis occurs predominantly in young women, classically during pregnancy or in the early postpartum period, and usually presents as symmetrical enlargement of the pituitary gland with marked homogeneous enhancement on MRI[23]. Granulomatous hypophysitis is characterized by a sellar mass with a tongue-like suprasellar and retrosellar extension, which sometimes infiltrates the basal hypothalamus[24]. Additionally, the possibility of metastases from other sites needs to be excluded in older adults. Depending on the site of the primary tumor, pituitary metastases often manifest as intrasellar or suprasellar masses with isointensity or hypointensity on T1WI, hyperintensity on T2WI, and strong post-gadolinium enhancement[25]. Although these characteristics are helpful in the differential diagnosis, they are not always present. Therefore, the diagnosis of these diseases still needs to be considered comprehensively.

Drug therapy is the first choice for the treatment of IgG4-RD. Glucocorticoids are the first-line drug for the majority of patients and most symptoms rapidly improve following the administration of glucocorticoid treatment. The response of IgG4-RD to glucocorticoids is related to the affected organs and the degree of fibrosis. They usually respond to glucocorticoids in the inflammatory stage, but relapse and refractory cases are not uncommon[26]. Therefore, early diagnosis and treatment are important. In addition, other diagnoses should be considered if the condition does not respond to glucocorticoids. Conventional steroid-sparing agents, such as azathioprine, mycophenolate mofetil, and methotrexate, can also be used for IgG4-RD, but comparative studies with glucocorticoids have not been conducted. Patients who do not respond to glucocorticoids and conventional steroid-sparing agents may respond to rituximab, but its efficacy and side effects need further study[7,27].

**CONCLUSION**

The incidence of IgG4-RH is much lower than that of pituitary adenoma. IgG4-RH occurs most frequently in middle-aged and older men and is characterized by hypopituitarism, hypointensity on T2WI, and obvious homogeneous enhancement on gadolinium contrast-enhanced T1WI. These findings should alert clinicians to the possibility of IgG4-RH. Overall, a diagnosis of IgG4-RD requires a comprehensive workup, including histology, imaging, serology, search for other organ involvement, and assessing the response to glucocorticoid therapy.

**REFERENCES**

1 **Bhatti RM**, Stelow EB. IgG4-related disease of the head and neck. *Adv Anat Pathol* 2013; **20**: 10-16 [PMID: 23232567 DOI: 10.1097/PAP.0b013e31827b619e]

2 **Baptista B**, Casian A, Gunawardena H, D'Cruz D, Rice CM. Neurological Manifestations of IgG4-Related Disease. *Curr Treat Options Neurol* 2017; **19**: 14 [PMID: 28374231 DOI: 10.1007/s11940-017-0450-9]

3 **Stone JH**, Khosroshahi A, Deshpande V, Chan JK, Heathcote JG, Aalberse R, Azumi A, Bloch DB, Brugge WR, Carruthers MN, Cheuk W, Cornell L, Castillo CF, Ferry JA, Forcione D, Klöppel G, Hamilos DL, Kamisawa T, Kasashima S, Kawa S, Kawano M, Masaki Y, Notohara K, Okazaki K, Ryu JK, Saeki T, Sahani D, Sato Y, Smyrk T, Stone JR, Takahira M, Umehara H, Webster G, Yamamoto M, Yi E, Yoshino T, Zamboni G, Zen Y, Chari S. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. *Arthritis Rheum* 2012; **64**: 3061-3067 [PMID: 22736240 DOI: 10.1002/art.34593]

4 **Tang H**, Ding G, Xiong J, Zhu H, Hua L, Xie Q, Gong Y. Clivus Inflammatory Pseudotumor Associated with Immunoglobulin G4-Related Disease. *World Neurosurg* 2018; **118**: 71-74 [PMID: 29966794 DOI: 10.1016/j.wneu.2018.06.174]

5 **Liu X**, Wang R, Li M, Chen G. IgG4-Related Inflammatory Pseudotumor Involving the Clivus: A Case Report and Literature Review. *Front Endocrinol (Lausanne)* 2021; **12**: 666791 [PMID: 33995286 DOI: 10.3389/fendo.2021.666791]

6 **AbdelRazek MA**, Venna N, Stone JH. IgG4-related disease of the central and peripheral nervous systems. *Lancet Neurol* 2018; **17**: 183-192 [PMID: 29413316 DOI: 10.1016/S1474-4422(17)30471-4]

7 **Kamisawa T**, Zen Y, Pillai S, Stone JH. IgG4-related disease. *Lancet* 2015; **385**: 1460-1471 [PMID: 25481618 DOI: 10.1016/S0140-6736(14)60720-0]

8 **Zen Y**, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. *Am J Surg Pathol* 2010; **34**: 1812-1819 [PMID: 21107087 DOI: 10.1097/PAS.0b013e3181f7266b]

9 **Deshpande V**, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, Klöppel G, Heathcote JG, Khosroshahi A, Ferry JA, Aalberse RC, Bloch DB, Brugge WR, Bateman AC, Carruthers MN, Chari ST, Cheuk W, Cornell LD, Fernandez-Del Castillo C, Forcione DG, Hamilos DL, Kamisawa T, Kasashima S, Kawa S, Kawano M, Lauwers GY, Masaki Y, Nakanuma Y, Notohara K, Okazaki K, Ryu JK, Saeki T, Sahani DV, Smyrk TC, Stone JR, Takahira M, Webster GJ, Yamamoto M, Zamboni G, Umehara H, Stone JH. Consensus statement on the pathology of IgG4-related disease. *Mod Pathol* 2012; **25**: 1181-1192 [PMID: 22596100 DOI: 10.1038/modpathol.2012.72]

10 **Bando H**, Iguchi G, Fukuoka H, Taniguchi M, Yamamoto M, Matsumoto R, Suda K, Nishizawa H, Takahashi M, Kohmura E, Takahashi Y. The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature. *Eur J Endocrinol* 2014; **170**: 161-172 [PMID: 24165017 DOI: 10.1530/EJE-13-0642]

11 **Caputo C**, Bazargan A, McKelvie PA, Sutherland T, Su CS, Inder WJ. Hypophysitis due to IgG4-related disease responding to treatment with azathioprine: an alternative to corticosteroid therapy. *Pituitary* 2014; **17**: 251-256 [PMID: 23794123 DOI: 10.1007/s11102-013-0498-9]

12 **Hattori Y**, Tahara S, Ishii Y, Kitamura T, Inomoto C, Osamura RY, Teramoto A, Morita A. A case of IgG4-related hypophysitis without pituitary insufficiency. *J Clin Endocrinol Metab* 2013; **98**: 1808-1811 [PMID: 23515454 DOI: 10.1210/jc.2013-1088]

13 **Shimatsu A**, Oki Y, Fujisawa I, Sano T. Pituitary and stalk lesions (infundibulo-hypophysitis) associated with immunoglobulin G4-related systemic disease: an emerging clinical entity. *Endocr J* 2009; **56**: 1033-1041 [PMID: 19926920 DOI: 10.1507/endocrj.k09e-277]

14 **Umehara H**, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S, Hamano H, Kamisawa T, Shimosegawa T, Shimatsu A, Nakamura S, Ito T, Notohara K, Sumida T, Tanaka Y, Mimori T, Chiba T, Mishima M, Hibi T, Tsubouchi H, Inui K, Ohara H. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. *Mod Rheumatol* 2012; **22**: 21-30 [PMID: 22218969 DOI: 10.1007/s10165-011-0571-z]

15 **Toyoda K**, Oba H, Kutomi K, Furui S, Oohara A, Mori H, Sakurai K, Tsuchiya K, Kan S, Numaguchi Y. MR imaging of IgG4-related disease in the head and neck and brain. *AJNR Am J Neuroradiol* 2012; **33**: 2136-2139 [PMID: 22700747 DOI: 10.3174/ajnr.A3147]

16 **Katsura M**, Mori H, Kunimatsu A, Sasaki H, Abe O, Machida T, Ohtomo K. Radiological features of IgG4-related disease in the head, neck, and brain. *Neuroradiology* 2012; **54**: 873-882 [PMID: 22358111 DOI: 10.1007/s00234-012-1012-1]

17 **Bhargava R**, Hussein Z, Dorward NL, Grieve JP, Jaunmuktane Z, Marcus HJ, Proctor I, Baldeweg SE. IgG4-related hypophysitis: a retrospective cohort study. *Acta Neurochir (Wien)* 2022 [PMID: 35532784 DOI: 10.1007/s00701-022-05231-9]

18 **Wright K**, Kim H, Hill T, Lee M, Orillac C, Mogar N, Pacione D, Agrawal N. Preoperative differentiation of hypophysitis and pituitary adenomas using a novel clinicoradiologic scoring system. *Pituitary* 2022 [PMID: 35622211 DOI: 10.1007/s11102-022-01232-0]

19 **Agustsson TT**, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. *Eur J Endocrinol* 2015; **173**: 655-664 [PMID: 26423473 DOI: 10.1530/EJE-15-0189]

20 **Zamora C**, Castillo M. Sellar and Parasellar Imaging. *Neurosurgery* 2017; **80**: 17-38 [PMID: 28362892 DOI: 10.1093/neuros/nyw013]

21 **Jipa A**, Jain V. Imaging of the sellar and parasellar regions. *Clin Imaging* 2021; **77**: 254-275 [PMID: 34153590 DOI: 10.1016/j.clinimag.2021.05.022]

22 **Kurokawa R**, Ota Y, Gonoi W, Hagiwara A, Kurokawa M, Mori H, Maeda E, Amemiya S, Usui Y, Sato N, Nakata Y, Moritani T, Abe O. MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis. *AJNR Am J Neuroradiol* 2020; **41**: 1683-1689 [PMID: 32763900 DOI: 10.3174/ajnr.A6692]

23 **Yang MG**, Cai HQ, Wang SS, Liu L, Wang CM. Full recovery from chronic headache and hypopituitarism caused by lymphocytic hypophysitis: A case report. *World J Clin Cases* 2022; **10**: 1041-1049 [PMID: 35127918 DOI: 10.12998/wjcc.v10.i3.1041]

24 **Unlu E**, Puyan FO, Bilgi S, Kemal Hamamcioglu M. Granulomatous hypophysitis: presentation and MRI appearance. *J Clin Neurosci* 2006; **13**: 1062-1066 [PMID: 17113990 DOI: 10.1016/j.jocn.2005.11.046]

25 **Caranci F**, Leone G, Ponsiglione A, Muto M, Tortora F, Muto M, Cirillo S, Brunese L, Cerase A. Imaging findings in hypophysitis: a review. *Radiol Med* 2020; **125**: 319-328 [PMID: 31863360 DOI: 10.1007/s11547-019-01120-x]

26 **Stone JH**, Zen Y, Deshpande V. IgG4-related disease. *N Engl J Med* 2012; **366**: 539-551 [PMID: 22316447 DOI: 10.1056/NEJMra1104650]

27 **Khosroshahi A**, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. *Arthritis Rheum* 2010; **62**: 1755-1762 [PMID: 20191576 DOI: 10.1002/art.27435]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 20, 2022

**First decision:** June 16, 2022

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Kurokawa R, Japan; Vujasinovic M, Sweden **S-Editor:** Fan JR **L-Editor:** Wang TQ **P-Editor:** Fan JR


**Figure Legends**



**Figure 1 Imaging findings of immunoglobin G4-related hypophysitis on computed tomography.** A: Axial unenhanced computed tomography (CT) scan; B: A well-defined, homogeneous, mild hyperdense mass measuring 2.5 cm × 2.3 cm × 1.8 cm in the sellar region, without bone destruction; C: Coronal CT showing the “hourglass sign” (arrow).



**Figure 2** **Imaging findings of immunoglobin G4-related hypophysitis on magnetic resonance imaging.** A and B: Coronal T2-weighted imaging (A) and sagittal T1-weighted imaging (B) showing an iso-hypointensity mass with an ”hourglass sign” in the sellar region; C and D: Sagittal (C) and coronal (D, arrow) contrast-enhanced T1-weighted imaging showing obvious homogeneous enhancement.



**Figure 3 Histological features of immunoglobin G4-related hypophysitis.** A: Hematoxylin and eosin staining showed abundant plasma cell and lymphocyte infiltration with local fibrosis (× 400); B: Immunohistochemical analysis showed immunoglobin G4 (IgG4) (+)/IgG (+) > 40%, and IgG4 (+) cells > 10/high-powered field (IgG, × 400); C: Immunohistochemical staining for Ki-67 showing cellular proliferation (× 100).